HaTay Pharmaceutical announces capital increase plan via new share issuance

HaTay Pharmaceutical JSC announced its plan to issue additional shares to increase its charter capital from owner's equity. The resolution from its board of directors, dated September 24, 2025, details the issuance of ordinary shares, with a par value of VND 10,000 per share. The company will issue a maximum of 8,234,026 shares, representing a 10% issuance ratio based on current outstanding shares.

The total expected value of this issuance at par is VND 82,340,260,000. This capital increase will primarily target existing shareholders listed as of the record date, with a 10:1 ratio, meaning shareholders will receive one new share for every ten shares held. The funding for this issuance will come from the company's undistributed post-tax profits and capital surplus, based on its audited 2024 financial statements. The issuance is projected to occur in Q3-Q4 2025.

The plan prioritizes using VND 22,300,000,000 from undistributed post-tax profits and then VND 60,040,260,000 from capital surplus. Notably, the newly issued shares will not have transfer restrictions. Fractions of shares will be rounded down to the nearest whole unit and cancelled. The foreign ownership ratio will remain unchanged by this issuance.